News

June 29, 2018

AIVITA Advances Phase 2 Clinical Trial for Ovarian Cancer Vaccine

News

AIVITA Biomedical has begun to randomize patients for a Phase 2 clinical trial assessing its cell-based immunotherapy for the treatment of newly-diagnosed advanced ovarian cancer. Currently recruiting participants at Hoag Memorial Hospital Presbyterian ... Read more

June 27, 2018

Mirvetuximab Soravtansine Given FDA Fast Track Designation for Ovarian Cancer Treatment

News

Mirvetuximab soravtansine (IMGN853), an investigational antibody-drug conjugate, has been granted fast track designation by the U.S. Food and Drug Administration for the treatment of ovarian cancer patients, ImmunoGen, the therapy’s maker, announced. The ... Read more

June 25, 2018

Splash Begins Expansion Phase of SPL-108 Trial for Ovarian Cancer Patients

News

Splash Pharmaceuticals has successfully completed the safety stage of its Phase 1 trial testing a combination of SPL-108 and chemotherapy in platinum-resistant ovarian cancer patients, the company announced in a press release. Taking ... Read more

June 22, 2018June 22, 2018

A Second Surgery Can Improve Survival for Women with Recurring Ovarian Cancer, Study Shows

News

Follow-up surgery to remove all traces of cancer can improve the survival of women whose ovarian cancer returned after initial surgery and chemotherapy, a Norwegian study shows. In the study, ... Read more

June 20, 2018

Zejula Added to UK’s Cancer Drugs Fund for Recurrent, Platinum-sensitive Ovarian Cancer

News

Women in England and Wales with recurrent, platinum-sensitive ovarian cancer can now access Zejula (niraparib) through the Cancer Drugs Fund (CDF) after a recommendation by the U.K.’s National Institute for Health and Care ... Read more

June 18, 2018June 18, 2018

FDA Approves Avastin in Combination with Chemotherapy as Treatment for Advanced Ovarian Cancers

News

The U.S. Food and Drug Administration (FDA) has approved the use of Avastin (bevacizumab) in combination with standard chemotherapy, followed by Avastin alone, as a front-line treatment for advanced ovarian ... Read more

June 15, 2018June 15, 2018

Phase 3 Trial Evaluating Add-on Tecentriq for Advanced Ovarian Cancer Is Recruiting Participants

News

A new Phase 3 trial will evaluate the potential of Tecentriq (atezolizumab) as an add-on therapy to Avastin (bevacizumab) plus chemotherapy in advanced ovarian cancer patients. The trial, called ATALANTE (NCT02891824), ... Read more

June 11, 2018

American Cancer Society Reports Covers Gains in Treatment and Prevention, and Challenges That Remain

News

By year’s end, about 22,240 new cases of ovarian cancer will be diagnosed in the United States, a newly released report from the American Cancer Society estimates. The report, titled “Ovarian ... Read more

June 8, 2018

Phase 3 Trial Testing Pamiparib as Maintenance Therapy for Ovarian Cancer Recruiting Patients in China

News

BeiGene has started enrollment in its Phase 3 clinical trial evaluating the investigational PARP inhibitor pamiparib (BGB-290) as a maintenance therapy for ovarian cancer patients who are responding to platinum-based chemotherapy. The ... Read more

June 6, 2018

Emotional Burden of Ovarian Cancer High But Often Overlooked, Review Aiming to ‘Amplify’ Patient Voice Reports

News

Ovarian cancer carries a considerable psychological burden for patients, especially for those with recurrent cancer, but care for patients’ emotional well-being is lacking, a literature review involving patients in Europe ... Read more